US Biosimilar Spending Poised For Substantial Growth By 2024, IQVIA Says

 
• By Jessica Merrill
Turning Point sign with clouds and sky background
IQVIA says the US biosimilar market has hit an inflection point • Source: Shutterstock

More from Strategy

More from Business